Toronto Memory Program

Toronto, Ontario M3B2S7

4 studies enrolling now · 42 studies all time

What they study most

Alzheimer Disease, Alzheimer Disease (AD), Alzheimer's Disease, Alzheimer's Disease, Early Onset, Alzheimers Disease, Alzheimer´s Disease, Behavioral Variant Frontotemporal Dementia, Behavioral Variant Frontotemporal Dementia (bvFTD), Brain Diseases, Central Nervous System Diseases, Cognitive Impairment, Dementia

Studies at this site

• A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease — Recruiting now
• Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies — Recruiting now
• A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease — Recruiting now
• Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia — Recruiting now
• Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects — Stopped early
• A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease — Running, not enrolling
• Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease — Running, not enrolling
• A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease — Completed
• AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid — Running, not enrolling
• A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ) — Completed
• Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens — Completed
• An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects — Completed
• Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease — Stopped early
• A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) — Running, not enrolling
• A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT) — Completed
• A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD) — Stopped early
• Open-label Extension for Phase 3 Clinical Trials of Simufilam — Stopped early
• Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients — Completed
• Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease — Completed
• A Study to Evaluate the Safety and Tolerability of Long-term Administration of Gantenerumab in Participants With Alzheimer's Disease (AD) — Stopped early
• Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD) — Stopped early
• A Study of Gantenerumab in Participants With Mild Alzheimer Disease — Completed
• A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's Disease — Paused
• Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease — Completed
• A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease — Completed
• A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease — Stopped early
• A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease — Completed
• A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB) — Completed
• A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease — Stopped early
• Tau Screening Study in Patients With Early Symptomatic AD — Completed
• A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia — Stopped early
• An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease — Stopped early
• A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia — Stopped early
• ELND005 in Patients With Mild to Moderate Alzheimer's Disease — Completed
• Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo — Completed
• Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD) — Completed
• Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease — Completed
• Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients — Stopped early
• Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease — Completed
• Effects of ONO-2506PO in Patients With Alzheimer's Disease — Completed
• 18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type — Completed
• Evaluation of 3APS in Patients With Mild to Moderate Alzheimer's Disease — Status unconfirmed